OBJECTIVES: To determine the cost-effectiveness and cost-utility of Tritace Comb (ramipril+ hydrochlorothiazide) compared to standard therapy of ramipril and hydrochlorothiazide (HCTZ) used in monotherapy and compared to compound therapy of captopril/HCTZ in the treatment of hypertension in Poland. METHODS: To gain data on clinical effectiveness of analyzed therapies the clinical effectiveness analysis based on systematic review of RCTs was conducted. Direct medical costs regarding drug costs and ambulatory treatment, second-line therapy, complications and adverse events valid from public payer perspective were taken into account in the model. Costs data were gained from National Health Fund in Poland and medical experts from cardiology and hypertension. Modelling method applied was a Markov model with a 32 year time horizon. Sensitivity analyses was performed. The analysis were done according to HTA guidelines in Poland. RESULTS: Statistically significant difference in hypertension reduction between ramipril/HCTZ and monotherapy with ramipril or HCTZ was revealed in favour of ramipril/HCTZ. No significant differences in safety profile were found. No significant differences in hypertension reduction were observed in comparison to combined therapy captopril/HCTZ but hypertension control was significantly longer for ramipril/HCTZ treatment. The analysis showed that incremental costs per LYGs were estimated at 1,515 PLN, 6,969 PLN, 10,733 PLN for ramipril/HCTZ compared to ramipril, HCTZ or combined therapy captopril/HCTZ, respectively. Incremental costs per QALY were estimated at 1,925 PLN, 8,800 PLN, 13,930 PLN when comparing ramipril/HCTZ with standard therapy of ramipril, HCTZ and captopril/HCTZ respectively. Sensitivity analysis showed that the results of the analysis are robust. CONCLUSIONS: Treatment of hypertension with Tritace comb (ramipril/HCTZ) compared with a standard mono therapy (ramipril, HCTZ) and with combined therapy captopril/HCTZ is very cost-effective option from the public payer’s perspective in Poland. Incremental costs per LYG and per QALYs are below the acceptable threshold for very cost-effectiveness treatment in Poland (27,000 PLN).